Molecular Templates, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Eric E. Poma
- Full Time Employees
- 62
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9301 Amberglen Boulevard Austin TX United States of America 78729
- IPO Date
- Feb 4, 2005
- CIK
- 0001183765
- Website
- mtem.com
- Similar Companies
- Business
- Molecular Templates, Inc. (Nasdaq: MTEMQ) is a clinical-stage biopharmaceutical company that discovers, develops, and commercializes engineered toxin bodies (ETBs), a proprietary platform of targeted biologic therapeutics leveraging a genetically engineered Shiga-like Toxin A subunit for potent cell-killing mechanisms in oncology and other serious diseases. The company's core pipeline includes MT-6402, a PD-L1-targeted ETB demonstrating monotherapy activity and partial responses in heavily pretreated solid tumors such as head and neck squamous cell carcinoma and non-small cell lung cancer; MT-8421, a CTLA-4-targeted ETB showing early monotherapy signals; and MT-0169, a CD38-targeted ETB under evaluation for relapsed/refractory multiple myeloma and potential autoimmune applications; with prior candidates like MT-5111 explored in HER2-expressing solid tumors. Founded in 2011 and headquartered in Austin, Texas (with recent correspondence address in Foxboro, Massachusetts), Molecular Templates targets cancer patients, including those with low-expression tumors resistant to conventional therapies, and operates primarily in the United States. In recent developments, the company received Nasdaq delisting notice in December 2024 for classification as a public shell, failure to file its Q3 2024 10-Q, and minimum bid price noncompliance, amid suspended clinical trials and restructuring due to insufficient resources; it ceased operations thereafter. Earlier in 2024, Molecular Templates reported Q2 financials with $9.7 million in cash supporting operations into Q4, alongside interim clinical updates on MT-6402's favorable safety and efficacy; completed a $9.5 million financing in April; and explored MT-0169 beyond oncology, though revenues declined sharply year-over-year. Historic strategic moves include a 2017 merger with Threshold Pharmaceuticals, $40 million equity financing, and a multi-target oncology collaboration with Takeda involving upfront payments, milestones, and royalties.
RapidPulse Secures Oversubscribed $48M Series B Financing to Advance Clinical Development of Next-Generation Stroke Aspiration Technology
Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules
Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements
Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update
Molecular Templates, Inc. Provides Interim Update
Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update
Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism
Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update
Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement
Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)
Molecular Templates, Inc. Provides Interim Update
Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update
Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors
Molecular Templates to Participate in Upcoming Investor Conferences
Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Molecular Templates Inc. (MTEM)
Molecular Templates Announces 1-for-15 Reverse Stock Split
Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update
Molecular Templates Announces Executive Leadership Changes